Ionis Pharmaceuticals IncNASDAQ:IONS
- LAST PRICE39.2900
- TODAY'S CHANGE (%)-0.2000 (-0.5065%)
- Bid / Lots39.2700/ 1
- Ask / Lots39.3100/ 2
- Open / Previous Close39.5300 / 39.4900
- Day Range
- 52 Week Range
- Volume721,812
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IONS |
|---|---|---|
| 09:32 ET | 14628 | 39.32 |
| 09:34 ET | 4177 | 39.23 |
| 09:36 ET | 1200 | 39.53 |
| 09:38 ET | 630 | 39.235 |
| 09:39 ET | 1300 | 39.105 |
| 09:41 ET | 800 | 39.01 |
| 09:43 ET | 4189 | 39.04 |
| 09:45 ET | 19057 | 39.29 |
| 09:48 ET | 1345 | 39.2 |
| 09:50 ET | 1213 | 39.3 |
| 09:52 ET | 600 | 39.42 |
| 09:54 ET | 3276 | 39.59 |
| 09:56 ET | 3257 | 39.565 |
| 09:57 ET | 1857 | 39.595 |
| 09:59 ET | 700 | 39.55 |
| 10:01 ET | 2725 | 39.4 |
| 10:03 ET | 2150 | 39.25 |
| 10:06 ET | 41498 | 39.31 |
| 10:08 ET | 1400 | 39.43 |
| 10:10 ET | 500 | 39.355 |
| 10:12 ET | 1612 | 39.37 |
| 10:14 ET | 100 | 39.39 |
| 10:15 ET | 2757 | 39.52 |
| 10:17 ET | 1800 | 39.75 |
| 10:19 ET | 808 | 39.64 |
| 10:21 ET | 680 | 39.55 |
| 10:24 ET | 2000 | 39.595 |
| 10:26 ET | 500 | 39.62 |
| 10:28 ET | 900 | 39.5 |
| 10:30 ET | 1000 | 39.67 |
| 10:32 ET | 1500 | 39.71 |
| 10:33 ET | 722 | 39.755 |
| 10:35 ET | 674 | 39.7502 |
| 10:37 ET | 700 | 39.66 |
| 10:39 ET | 2240 | 39.63 |
| 10:42 ET | 500 | 39.535 |
| 10:44 ET | 1165 | 39.53 |
| 10:46 ET | 22965 | 39.625 |
| 10:48 ET | 1700 | 39.64 |
| 10:50 ET | 500 | 39.78 |
| 10:51 ET | 1733 | 39.74 |
| 10:53 ET | 6391 | 39.69 |
| 10:55 ET | 830 | 39.69 |
| 10:57 ET | 1200 | 39.715 |
| 11:00 ET | 2750 | 39.62 |
| 11:02 ET | 400 | 39.72 |
| 11:04 ET | 200 | 39.7 |
| 11:06 ET | 1305 | 39.6825 |
| 11:08 ET | 200 | 39.67 |
| 11:09 ET | 300 | 39.61 |
| 11:11 ET | 400 | 39.57 |
| 11:13 ET | 6062 | 39.485 |
| 11:15 ET | 3577 | 39.42 |
| 11:18 ET | 62563 | 39.4 |
| 11:20 ET | 58981 | 39.215 |
| 11:22 ET | 999 | 39.29 |
| 11:24 ET | 3000 | 39.28 |
| 11:26 ET | 900 | 39.46 |
| 11:27 ET | 1000 | 39.37 |
| 11:29 ET | 300 | 39.405 |
| 11:31 ET | 1450 | 39.4 |
| 11:33 ET | 200 | 39.415 |
| 11:36 ET | 24949 | 39.49 |
| 11:38 ET | 158307 | 39.38 |
| 11:40 ET | 3719 | 39.42 |
| 11:42 ET | 302 | 39.425 |
| 11:44 ET | 907 | 39.3776 |
| 11:47 ET | 200 | 39.33 |
| 11:49 ET | 54093 | 39.11 |
| 11:51 ET | 1992 | 39.09 |
| 11:54 ET | 400 | 39.16 |
| 11:56 ET | 241 | 39.23 |
| 11:58 ET | 1801 | 39.15 |
| 12:00 ET | 200 | 39.065 |
| 12:02 ET | 500 | 39.03 |
| 12:03 ET | 1200 | 39.116 |
| 12:05 ET | 458 | 39.1 |
| 12:07 ET | 800 | 39.18 |
| 12:09 ET | 900 | 39.15 |
| 12:12 ET | 2414 | 39.12 |
| 12:14 ET | 1200 | 39.18 |
| 12:16 ET | 670 | 39.15 |
| 12:18 ET | 1265 | 39.13 |
| 12:20 ET | 903 | 39.16 |
| 12:21 ET | 1451 | 39.25 |
| 12:23 ET | 1433 | 39.35 |
| 12:25 ET | 540 | 39.395 |
| 12:27 ET | 1621 | 39.33 |
| 12:30 ET | 867 | 39.33 |
| 12:32 ET | 1000 | 39.2 |
| 12:34 ET | 800 | 39.31 |
| 12:36 ET | 202 | 39.3 |
| 12:38 ET | 500 | 39.325 |
| 12:39 ET | 800 | 39.29 |
| 12:41 ET | 700 | 39.255 |
| 12:43 ET | 1900 | 39.25 |
| 12:45 ET | 800 | 39.29 |
| 12:48 ET | 800 | 39.26 |
| 12:50 ET | 200 | 39.185 |
| 12:52 ET | 300 | 39.205 |
| 12:54 ET | 2600 | 39.17 |
| 12:56 ET | 52000 | 39.31 |
| 12:57 ET | 658 | 39.32 |
| 12:59 ET | 700 | 39.34 |
| 01:01 ET | 400 | 39.29 |
| 01:03 ET | 500 | 39.29 |
May 12, 2022
Ionis to present at RBC Capital Markets Global Healthcare Conference, from 7:05AM ET on Thursday May 12, 2022 by PR Newswire
7:05AM ET on Thursday May 12, 2022 by PR Newswire
May 9, 2022
--Morgan Stanley Trims Ionis Pharmaceuticals Price Target to $30 From $31, Underweight Rating Kept, from 12:05PM ET on Monday May 09, 2022 by MT Newswires
12:05PM ET on Monday May 09, 2022 by MT Newswires
May 6, 2022
--Stifel Adjusts Price Target on Ionis Pharmaceuticals to $33 From $31, Reiterates Hold Rating, from 9:11AM ET on Friday May 06, 2022 by MT Newswires
9:11AM ET on Friday May 06, 2022 by MT Newswires
May 4, 2022
Ionis Pharmaceuticals Q1 Loss Narrows, Revenue Rises, from 8:36AM ET on Wednesday May 04, 2022 by MT Newswires
8:36AM ET on Wednesday May 04, 2022 by MT NewswiresBRIEF-Ionis Reports First Quarter Financial Results , from 8:25AM ET on Wednesday May 04, 2022 by Thomson Reuters
8:25AM ET on Wednesday May 04, 2022 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ionis Pharmaceuticals Inc | 5.6B | -1,423.0x | --- |
Sarepta Therapeutics Inc | 6.2B | -17.1x | --- |
Azenta Inc | 5.2B | -225.7x | --- |
CRISPR Therapeutics AG | 4.4B | 15.2x | --- |
Halozyme Therapeutics Inc | 6.1B | 14.9x | --- |
Alkermes Plc | 4.9B | -77.4x | --- |
Company Information
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on our cardiovascular and neurology franchises. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The Company has over six medicines in Phase III studies for eight indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) and Tofersen (SOD1). Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen and IONIS-AGT-LRx.
Contact Information
- Headquarters
- 2855 Gazelle CtCARLSBAD, CA, United States 92010-6670
- Phone
- 760-931-9200
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Loscalzo
- Chief Executive Officer, Director
- Brett Monia
- Chief Financial Officer, Executive Vice President - Finance
- Elizabeth Hougen
- Executive Vice President, Chief Scientific Officer
- C. Frank Bennett
- Executive Vice President, Chief Business Officer
- Joseph Baroldi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.6B |
|---|---|
Revenue (TTM) | $840.8M |
Shares Outstanding | 141.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-0.03 |
Book Value | $5.47 |
P/E Ratio | -1,423.0x |
Price/Sales (TTM) | 6.7 |
Price/Cash Flow (TTM) | 406.4x |
Operating Margin | -0.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
